Report overview
The global Erythropoietin Biosimilar market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Hospital Pharmacy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Erythropoietin Biosimilar include Pfizer, VHB Life Sciences, Chengdu Di'Ao Pharmaceutical Group, Chalver Laboratorios, Fresenius Kabi, Neiss Labs, Micro Labs, Zuventus Healthcare and RPG Life Sciences, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Erythropoietin (EPO) is the major glycoprotein hormone regulator of mammalian erythropoiesis , and is produced by kidney and liver in an oxygen-dependent manner. The biological effects of EPO are mediated by the specific erythropoietin receptor (EPOR) on bone marrow erythroblasts, which transmits signals important for both proliferation and differentiation along the erythroid lineage. EPOR is a type 1 single-transmembrane cytokine receptor, and belongs to the homodimerizing subclass which functions as ligand-induced or ligand-stabilized homodimers. EPOR pre-exists as dimers which upon binding of a 34 kDa ligand erythropoietin (Epo), changes its homodimerized state. These conformational changes result in the autophosphorylation of Jak2 kinases that are pre-associated with the receptor. Erythropoietin is necessary to maintain endothelial cells and to promote tumor angiogenesis, hence the dysregulation of EpoR may affect the growth of certain tumors. EpoR signaling prevents neuronal death and ischemic injury.
This report aims to provide a comprehensive presentation of the global market for Erythropoietin Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Erythropoietin Biosimilar. This report contains market size and forecasts of Erythropoietin Biosimilar in global, including the following market information:
Global Erythropoietin Biosimilar Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global Erythropoietin Biosimilar Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five Erythropoietin Biosimilar companies in 2023 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Erythropoietin Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Erythropoietin Biosimilar Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Erythropoietin Biosimilar Market Segment Percentages, by Type, 2023 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Erythropoietin Biosimilar Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Erythropoietin Biosimilar Market Segment Percentages, by Application, 2023 (%)
Hematology
Kidney Disorder
Cancer
Others
Global Erythropoietin Biosimilar Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Erythropoietin Biosimilar Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Erythropoietin Biosimilar revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Erythropoietin Biosimilar revenues share in global market, 2023 (%)
Key companies Erythropoietin Biosimilar sales in global market, 2019-2024 (Estimated), (K Units)
Key companies Erythropoietin Biosimilar sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
VHB Life Sciences
Chengdu Di'Ao Pharmaceutical Group
Chalver Laboratorios
Fresenius Kabi
Neiss Labs
Micro Labs
Zuventus Healthcare
RPG Life Sciences
Unilab
Incepta Pharmaceuticals
Genius Biotherapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Erythropoietin Biosimilar, market overview.
Chapter 2: Global Erythropoietin Biosimilar market size in revenue and volume.
Chapter 3: Detailed analysis of Erythropoietin Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Erythropoietin Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Erythropoietin Biosimilar capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
